Immunologic desensitization to nilotinib in a patient with chronic myeloid leukemia with hypersensitivity and complex
Triaji Suryo Condro Widagdo1, Deasy Fetarayani2,3, Wita Kartika Nurani2,3
1Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
The Journal of Allergy and Clinical Immunology. Global
|April 20, 2026
Abstract:
Desensitization to nilotinib offers a viable solution for patients with chronic myeloid leukemia who are experiencing hypersensitivity, thus enabling continuation of targeted therapy. This approach supports molecular remission even in the presence of complex metabolic and neurologic comorbidities.


